JP2005514030A - Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 - Google Patents

Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 Download PDF

Info

Publication number
JP2005514030A
JP2005514030A JP2003558131A JP2003558131A JP2005514030A JP 2005514030 A JP2005514030 A JP 2005514030A JP 2003558131 A JP2003558131 A JP 2003558131A JP 2003558131 A JP2003558131 A JP 2003558131A JP 2005514030 A JP2005514030 A JP 2005514030A
Authority
JP
Japan
Prior art keywords
binding
binding protein
polypeptide
binding site
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003558131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514030A5 (enExample
Inventor
エドムンド、ロッシー
チェーン‐シン、ケン、チャン
デイビッド、ゴールデンバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
IBC Pharmaceuticals Inc
Original Assignee
Immunomedics Inc
IBC Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, IBC Pharmaceuticals Inc filed Critical Immunomedics Inc
Publication of JP2005514030A publication Critical patent/JP2005514030A/ja
Publication of JP2005514030A5 publication Critical patent/JP2005514030A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003558131A 2001-12-26 2002-12-26 Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法 Withdrawn JP2005514030A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34210301P 2001-12-26 2001-12-26
PCT/US2002/038985 WO2003057829A2 (en) 2001-12-26 2002-12-26 Methods of generating multispecific, multivalent agents from vh and vl domains

Publications (2)

Publication Number Publication Date
JP2005514030A true JP2005514030A (ja) 2005-05-19
JP2005514030A5 JP2005514030A5 (enExample) 2006-02-23

Family

ID=23340336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558131A Withdrawn JP2005514030A (ja) 2001-12-26 2002-12-26 Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法

Country Status (12)

Country Link
US (1) US20030162709A1 (enExample)
EP (1) EP1468097A4 (enExample)
JP (1) JP2005514030A (enExample)
KR (1) KR20040091616A (enExample)
AU (1) AU2002364531A1 (enExample)
BR (1) BR0215403A (enExample)
CA (1) CA2471868A1 (enExample)
IL (1) IL162732A0 (enExample)
MX (1) MXPA04006327A (enExample)
PL (1) PL372144A1 (enExample)
RU (1) RU2004122702A (enExample)
WO (1) WO2003057829A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513476A (ja) * 2014-04-13 2017-06-01 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 三機能性抗原結合分子
JP2018537415A (ja) * 2015-10-13 2018-12-20 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 多価Ｆｖ抗体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN1604910A (zh) * 2001-10-15 2005-04-06 免疫医疗公司 亲和性增强物质
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
ES2871905T3 (es) 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
EP1587550B1 (en) * 2003-01-31 2011-07-27 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
EP1618181B1 (en) * 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
CN1326881C (zh) * 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
US9339559B2 (en) 2005-09-09 2016-05-17 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2007030802A2 (en) * 2005-09-09 2007-03-15 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2518155B1 (en) 2006-08-04 2014-07-23 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
CA2671431C (en) 2006-12-14 2019-03-26 Georgia State University Research Foundation, Inc. Analyte sensors, methods for preparing and using such sensors, and methods of detecting analyte activity
WO2009146099A2 (en) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2013184786A2 (en) * 2012-06-05 2013-12-12 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
US11571476B2 (en) 2017-12-11 2023-02-07 Taipei Medical University Anti-tumor/anti-tumor associated fibroblast/anti-hapten trispecific antibodies and use thereof
TWI870708B (zh) * 2017-12-12 2025-01-21 臺北醫學大學 多特異性抗體及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088994B1 (en) * 1982-03-15 1991-06-19 Schering Corporation Hybrid dna, binding composition prepared thereby and processes therefor
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
WO1994007921A1 (en) * 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
BR9606706A (pt) * 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
CA2249320C (en) * 1996-03-20 2008-12-23 Immunomedics, Inc. Glycosylated humanized b-cell specific antibodies
ES2225961T3 (es) * 1996-04-04 2005-03-16 Unilever N.V. Proteina de union a antigeno multivalente y multiespecifica.
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP4113670B2 (ja) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513476A (ja) * 2014-04-13 2017-06-01 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 三機能性抗原結合分子
JP2018537415A (ja) * 2015-10-13 2018-12-20 アッフィメッド・ゲー・エム・ベー・ハーＡｆｆｉｍｅｄ Ｇｍｂｈ 多価Ｆｖ抗体

Also Published As

Publication number Publication date
KR20040091616A (ko) 2004-10-28
MXPA04006327A (es) 2005-07-13
AU2002364531A1 (en) 2003-07-24
US20030162709A1 (en) 2003-08-28
WO2003057829A2 (en) 2003-07-17
WO2003057829A3 (en) 2004-02-26
CA2471868A1 (en) 2003-07-17
EP1468097A4 (en) 2006-01-11
PL372144A1 (en) 2005-07-11
RU2004122702A (ru) 2005-04-20
BR0215403A (pt) 2005-05-03
IL162732A0 (en) 2005-11-20
EP1468097A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
JP2005514030A (ja) Ｖｈおよびｖｌドメインから多重特異性多価薬剤を製造する方法
Kipriyanov et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
CA2555503C (en) Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
US8829175B2 (en) Nucleic acids encoding polyvalent protein complexes
AU2003209447B8 (en) RS7 antibodies
US20030148409A1 (en) Direct targeting binding proteins
Zhang et al. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy
JP2005526044A5 (enExample)
Gao et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein× anti-CD3 diabody
US9611321B2 (en) Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies
CN114195894B (zh) 一种靶向4-1bb的抗体及其应用
JP2023516906A (ja) 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用
EP1444267B1 (en) Affinity enhancement agents
AU2002335808A1 (en) Affinity enhancement agents
WO2023116781A1 (zh) 一种新型pd1单域抗体的开发
CN115698085A (zh) 一种抗pd-l1和egfr的四价双特异性抗体
JPWO2022109611A5 (enExample)
CN118480130A (zh) 靶向msln的抗体、嵌合抗原受体及其应用
AU2002348437A1 (en) Direct targeting binding proteins
Marlind et al. Tumor vascular targeting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060822